Evidence map›Paper›PMID 38601743›Full record

ArticleProceedings of the ... ACM International Conference on Information & Knowledge Management. ACM International Conference on Information and Knowledge Management2023

pADR: Towards Personalized Adverse Drug Reaction Prediction by Modeling Multi-sourced Data.

Junyu Luo, Cheng Qian, Xiaochen Wang, Lucas Glass, Fenglong Ma

Open access · greenAbstract read
In one paragraph

Article in Proceedings of the ... ACM International Conference on Information & Knowledge Management. ACM International Conference on Information and Knowledge Management, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.2field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 1 citations in OpenAlex.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Junyu LuoThe Pennsylvania State University, University Park, USA.
Cheng QianIQVIA, Chicago, USA.
Xiaochen WangThe Pennsylvania State University, University Park, USA.
Lucas GlassIQVIA, Chicago, USA.
Fenglong MaThe Pennsylvania State University, University Park, USA.
Pennsylvania State University · USIQVIA (United States) · US

Funding

SCH: AI-Enhanced Multimodal Sensor-on-a-chip for Alzheimer's Disease DetectionR01AG077016 · NIA · PENNSYLVANIA STATE UNIVERSITY, THE · PI HU, JUEJUN, MA, FENGLONG · 2022 to 2025
$1.2M
NIA NIH HHS R01 AG077016
6 · The paper itself

Abstract

Predicting adverse drug reactions (ADRs) of drugs is one of the most critical steps in drug development. By pre-estimating the adverse reactions, researchers and drug development companies can greatly prevent the potential ADR risks and tragedies. However, the current ADR prediction methods suffer from several limitations. First, the prediction results are based on pure drug-related information, which makes them impossible to be directly applied for the personalized ADR prediction task. The lack of personalization of models also makes rare adverse events hard to be predicted. Therefore, it is of great interest to develop a new personalized ADR prediction method by introducing additional sources, e.g., patient health records. However, few methods have tried to use additional sources. In the meantime, the variety of different source formats and structures makes this task more challenging. To address the above challenges, we propose a novel personalized multi-sourced-based drug adverse reaction prediction model named pADR. pADR first works on every single source to transform them into proper representations. Next, a hierarchical multi-sourced Transformer is designed to automatically model the interactions between different sources and fuse them together for the final adverse event prediction. Experimental results on a new multi-sourced ADR prediction dataset show that PADR outperforms state-of-the-art drug-based baselines. Moreover, the case and ablation studies also illustrate the effectiveness of our proposed fusion strategies and the reasonableness of each module design.

Indexed as

adverse drug reactionmultisourced data aggregationpersonalization

Identifiers

PMID38601743
PMCPMC11005853
OpenAlexW4387849020

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.